A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period (NCT06524375)
Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Springdale, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Highlands Oncology Group — Springdale, Arkansas
- Rocky Mountain Cancer Centers (Aurora) - USOR — Aurora, Colorado
- Cancer Specialists of North Florida — Jacksonville, Florida
- Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
- Mission Blood and Cancer - MercyOne Cancer Center — Des Moines, Iowa
- American Oncology Partners of Maryland, PA — Bethesda, Maryland
- Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center — Boston, Massachusetts
- Nebraska Cancer Specialists St Francis - Grand Island — Grand Island, Nebraska
- Nebraska Cancer Specialists — Omaha, Nebraska
- Astera Cancer Care East Brunswick — East Brunswick, New Jersey
- San Juan Oncology Associates, PC — Farmington, New Mexico
- Oncology Hematology Care Inc - Cincinnati - USOR — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Asante Rogue Regional Medical Center — Medford, Oregon
- Tennessee Oncology, PLLC - Chattanooga — Chattanooga, Tennessee
- Tennessee Oncology - Midtown — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology- Northeast Texas — Tyler, Texas
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.